1262310-00-8 Usage
Description
Tert-butyl 1-(Methylsulfonyl)piperidin-3-ylcarbaMate, also known as Tert-butyl 1-(MSPp)-3-ylcarbaMate, is a carbamate derivative featuring a tert-butyl group and a piperidine ring with a methylsulfonyl substituent. This chemical compound holds promise for pharmaceutical applications, particularly as a muscarinic receptor antagonist, which may offer therapeutic benefits in various conditions.
Uses
Used in Pharmaceutical Industry:
Tert-butyl 1-(Methylsulfonyl)piperidin-3-ylcarbaMate is used as a muscarinic receptor antagonist for its potential therapeutic applications in treating cardiovascular diseases, overactive bladder, and central nervous system disorders. Its antagonistic properties towards muscarinic receptors may help in managing symptoms and conditions related to these areas.
Research is ongoing to further elucidate the pharmacological properties of Tert-butyl 1-(Methylsulfonyl)piperidin-3-ylcarbaMate and to explore its potential for drug development, indicating that its applications may expand as more information becomes available.
Check Digit Verification of cas no
The CAS Registry Mumber 1262310-00-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,6,2,3,1 and 0 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1262310-00:
(9*1)+(8*2)+(7*6)+(6*2)+(5*3)+(4*1)+(3*0)+(2*0)+(1*0)=98
98 % 10 = 8
So 1262310-00-8 is a valid CAS Registry Number.
1262310-00-8Relevant articles and documents
Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe
R?hm, Sandra,Berger, Benedict-Tilman,Schr?der, Martin,Chatterjee, Deep,Mathea, Sebastian,Joerger, Andreas C.,Pinkas, Daniel M.,Bufton, Joshua C.,Tjaden, Amelie,Kovooru, Lohitesh,Kudolo, Mark,Pohl, Christian,Bullock, Alex N.,Müller, Susanne,Laufer, Stefan,Knapp, Stefan
, p. 13451 - 13474 (2021/09/28)
Discoidin domain receptors 1 and 2 (DDR1/2) play a central role in fibrotic disorders, such as renal and pulmonary fibrosis, atherosclerosis, and various forms of cancer. Potent and selective inhibitors, so-called chemical probe compounds, have been developed to study DDR1/2 kinase signaling. However, these inhibitors showed undesired activity on other kinases such as the tyrosine protein kinase receptor TIE or tropomyosin receptor kinases, which are related to angiogenesis and neuronal toxicity. In this study, we optimized our recently published p38 mitogen-activated protein kinase inhibitor7toward a potent and cell-active dual DDR/p38 chemical probe and developed a structurally related negative control. The structure-guided design approach used provided insights into the P-loop folding process of p38 and how targeting of non-conserved amino acids modulates inhibitor selectivity. The developed and comprehensively characterized DDR/p38 probe,30(SR-302), is a valuable tool for studying the role of DDR kinase in normal physiology and in disease development.
